Abstract：Objective: To observe the clinical efficacy of apatinib and tigio for patients with advanced refractory ovarian cancer (OC),and to explore the effect of the above drugs on human epididymal secretory protein 4(HE4),carbohydrate antigen 125(CA125) and carbohydrate antigen 199(CA199). Methods: Retrospective analysis was conducted of 88 patients with refractory OC from April 2018 to September 2019(TNM Ⅲ-Ⅳ),who were divided into observation group (treated with apatinib mesylate) and control group (treated with tigio),with 44 cases in each. The changes of HE4,CA125 and CA199 were compared between the two groups. The total effective rates,disease control rates and adverse reactions were compared between the two groups. Results: After treatment,the total effective rate of observation group was 50.00%,which was significantly higher than that of control group (P<0.05). The serum HE4,CA125,CA199 levels in the observation group decreased significantly compared with those in the control group (all P<0.05). The rates of non-hematological and hematological adverse reactions were 75.00% and 77.27% in the control group after treatment; there was a significant increase in 52.27% and 36.36% of the observation group (all P<0.05). Conclusion: Apatinib treatment for advanced refractory OC patients is ideal,with less adverse reactions and better disease control. It is considered to be related to the obvious inhibition of apatinib HE4、CA125、CA199 level,which has clinical value.
刘建婷, 张荣生, 邓天丽, 侯松萍. 替吉奥阿帕替尼治疗晚期难治性卵巢癌的疗效对比及药物对HE4 CA125及CA199的影响[J]. 河北医学, 2021, 27(3): 512-516.
LIU Jianting, ZHANG Rongsheng, DENG Tianli, et al. Comparison of Efficacy of Teguio and Apatinib in the Treatment of Advanced Refractory Ovarian Cancer and the Effect of Drugs on HE4 CA125 and CA199. HeBei Med, 2021, 27(3): 512-516.
2021, Vol. 27 
冀公网安备13080202000677号